文献速递血液净化与透析慢性肾脏病

ASCEND-D试验透析患者设计与基线特征

Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial.
PubMed 文献 · Nephrol Dial Transplant · 2022-01-01

ASCEND-D试验旨在验证达普司他与促红细胞生成素α或达贝泊汀α相比,在透析的CKD G5D贫血患者中血红蛋白疗效和心血管安全性的非劣效性。本文报告了2964例随机患者的试验设计、基线人口学、临床和实验室特征及基线治疗,并与其它大型CVOT及登记研究中的透析患者比较,显示基线特征相似。

要点

  • ASCEND-D试验纳入2964例透析的CKD G5D贫血患者,随机接受达普司他或促红细胞生成素α/达贝泊汀α治疗。
  • 患者中位年龄58岁,43%女性,89%接受血液透析,11%腹膜透析。
  • 基线中位血红蛋白10.4 g/dL,42%有糖尿病史,45%有心血管疾病史。

核心结论

  • ASCEND-D试验将评估达普司他对比促红细胞生成素α或达贝泊汀α在CKD G5D贫血患者中的疗效与安全性。

研究设计与样本

  • ASCEND-D为开放标签(申办者设盲)、活性对照、平行组、随机临床试验,共随机2964例透析的CKD G5D贫血患者。

主要发现

  • 患者中位年龄58岁,43%为女性,67%为白人,16%为黑人,基线中位血红蛋白10.4 g/dL。
  • 89%接受血液透析,11%接受腹膜透析,42%有糖尿病史,45%有心血管疾病史。
  • 中位血压134/74 mmHg,中位每周促红细胞生成素剂量5751单位,静脉和口服铁剂使用率分别为64%和11%。
  • 基线人口学特征与其它大型心血管结局试验及肾脏登记研究中的CKD G5D患者相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Anemia Studies in chronic kidney disease (CKD): Erythropoiesis via a Novel prolyl hydroxylase inhibitor Daprodustat-Dialysis (ASCEND-D) trial will test the hypothesis that daprodustat is noninferior to comparator epoetin alfa or darbepoetin alfa for two co-primary endpoints: hemoglobin (Hb) efficacy and cardiovascular (CV) safety. METHODS: We report the trial design, key demographic, clinical and laboratory findings, and baseline therapies of 2964 patients randomized in the open-label (sponsor-blinded) active-controlled, parallel-group, randomized ASCEND-D clinical trial. We also compare baseline characteristics of ASCEND-D patients with patients who are on dialysis (CKD G5D) enrolled in other large CV outcome trials (CVOTs) and in the most relevant registries. RESULTS: The median age of patients was 58 years, 43% were female; 67% were White and 16% were Black. The median Hb at baseline was 10.4 g/dL. Among randomized patients, 89% were receiving hemodialysis and 11% peritoneal dialysis. Among key comorbidities, 42% reported a history of diabetes mellitus and 45% a history of CV disease. Median blood pressure was 134/74 mmHg. The median weekly dose of epoetin was 5751 units. Intravenous and oral iron uses were noted in 64 and 11% of patients, respectively. Baseline demographics were similar to patients with CKD G5D enrolled in other CVOTs and renal patient registries. CONCLUSIONS: ASCEND-D will evaluate the efficacy and safety of daprodustat compared with epoetin alfa or darbepoetin alfa in the treatment of patients with anemia with CKD G5D.This trial is registered with ClinicalTrials.gov: NCT02879305. EudraCT Number: 2016-000541-31; Sponsor Protocol Number: 200807.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Singh AK, Blackorby A, Cizman B, et al. Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Nephrol Dial Transplant. 2022. PMID: 33744933. doi:10.1093/ndt/gfab065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。